Press release
Benign Prostatic Hyperplasia - Drug Pipeline Landscape, 2022 | AiViva BioPharma, Antev Ltd., ASKA Pharmaceutical Co., Ltd, Ausio Pharmaceuticals, LLC, Dongkook Pharmaceutical
Benign Prostatic Hyperplasia - Drug Pipeline Landscape, 2022
Benign Prostatic Hyperplasia (BPH) also called as prostate gland enlargement, is a noncancerous increase in size of the prostate gland. An enlarged prostate gland can cause uncomfortable urinary symptoms, such as blocking the flow of urine out of the bladder.
The common causes of BPH include changes in male sex hormones, any family history of prostate problems or any abnormalities with testicles risk of BPH.
Symptoms include incomplete bladder emptying, leakage of urine, obstructing the flow of urine, frequent or urgent need to urinate, increased frequency of urination at night (nocturia), difficulty starting urination, dribbling at the end of urination.
To know more about Benign Prostatic Hyperplasia, visit - https://www.globalinsightservices.com/reports/benign-prostatic-hyperplasia-drug-pipeline-landscape-2022/
Key Players :
• AiViva BioPharma
• Antev Ltd.
• ASKA Pharmaceutical Co., Ltd
• Ausio Pharmaceuticals, LLC
• Dongkook Pharmaceutical Co., Ltd.
• GemVax & Kael
• Health Ever Bio-Tech Co., Ltd.
• Nymox Corporation
• Urovant Sciences GmbH
Report Segmentation :
Assessment by Stage of Development
Assessment by Companies
Assessment by Target
Assessment by Mechanism of Action
Assessment by Molecule Type
Assessment by Route of Administration
Request for a PDF sample copy of report: https://www.globalinsightservices.com/request-sample/GIS31030
Report Highlights
Global Insight Service's, Benign Prostatic Hyperplasia - Drug Pipeline Landscape, 2022 report provides an overview of the Benign Prostatic Hyperplasia drugs. This report covers detailed insights on Benign Prostatic Hyperplasia drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Benign Prostatic Hyperplasia report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Buy this report: https://www.globalinsightservices.com/inquiry-before-buying/GIS31030
With Global Insight Services, you receive:
• 10-year forecast to help you make strategic decisions
• In-depth segmentation which can be customized as per your requirements
• Free consultation with lead analyst of the report
• Excel data pack included with all report purchases
• Robust and transparent research methodology
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Benign Prostatic Hyperplasia - Drug Pipeline Landscape, 2022 | AiViva BioPharma, Antev Ltd., ASKA Pharmaceutical Co., Ltd, Ausio Pharmaceuticals, LLC, Dongkook Pharmaceutical here
News-ID: 2785799 • Views: …
More Releases from Global Insight Services
Swarm Intelligence Market is anticipated to expand from $0.1 billion in 2024 to …
The Spinal Imaging Market is witnessing steady growth as healthcare providers increasingly rely on advanced imaging technologies to diagnose and monitor spinal disorders. The market comprises imaging modalities such as MRI, CT scans, X-rays, and emerging techniques including PET scans and ultrasound imaging. These technologies play a critical role in early detection, precise diagnosis, and effective treatment planning for spinal conditions such as degenerative disorders, tumors, infections, and trauma. The…
Custom Antibody Market: Growth Supported by Growing Applications in Immunotherap …
The Spinal Imaging Market is witnessing steady growth as healthcare providers increasingly rely on advanced imaging technologies to diagnose and monitor spinal disorders. The market comprises imaging modalities such as MRI, CT scans, X-rays, and emerging techniques including PET scans and ultrasound imaging. These technologies play a critical role in early detection, precise diagnosis, and effective treatment planning for spinal conditions such as degenerative disorders, tumors, infections, and trauma. The…
Liver Disease Treatment Market: Expansion Fueled by Increasing Incidence of NAFL …
The Liver Disease Treatment Market continues to expand rapidly as global awareness, early diagnosis, and advanced therapeutic approaches reshape patient care. With the market valued at $26.6 billion in 2024 and projected to reach $44.8 billion by 2034 at a steady 5.4% CAGR, demand for effective and accessible therapies is on the rise. The Liver Disease Treatment Market covers pharmaceuticals, biologics, vaccines, diagnostics, and liver transplant services designed to manage…
Healthcare Supply Chain BPO Market: Expansion Fueled by Increasing Outsourcing o …
The Healthcare Supply Chain BPO Market is rapidly evolving as healthcare providers worldwide seek smarter, leaner, and more resilient operations. With growing pressure to reduce costs, boost efficiency, and maintain uninterrupted patient care, outsourcing supply chain tasks has become a strategic necessity. The global Healthcare Supply Chain BPO Market is projected to grow from $3.05 billion in 2024 to $4.83 billion by 2034, reflecting a CAGR of 4.7%. This expansion…
More Releases for Benign
Rising Geriatric Population Drives Growth Of Benign Prostatic Hypertrophy Drugs …
The Drugs For Benign Prostatic hypertrophy Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Drugs For Benign Prostatic hypertrophy Market?
The drugs for benign prostatic hypertrophy market has shown strong growth, expanding from $4.28 billion in 2024 to $4.58…
Prominent Drugs For Benign Prostatic hypertrophy Market Trend for 2025: Innovati …
What Are the Projected Growth and Market Size Trends for the Drugs For Benign Prostatic hypertrophy Market?
The market size for benign prostatic hypertrophy medication has seen considerable growth in recent years. It is projected to increase from $4.28 billion in 2024 to $4.58 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. The significant growth during the historic period can be linked to an aging population, heightened…
Shaping the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment M …
How Big Is the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, there has been robust growth in the market size of benign prostatic hyperplasia (BPH) treatment devices and equipment. The market, which stood at $1.29 billion in 2024, is anticipated to increase to $1.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%.…
Prominent Drugs For Benign Prostatic hypertrophy Market Trend for 2025: Innovati …
What Are the Projected Growth and Market Size Trends for the Drugs For Benign Prostatic hypertrophy Market?
The market size for benign prostatic hypertrophy medication has seen considerable growth in recent years. It is projected to increase from $4.28 billion in 2024 to $4.58 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. The significant growth during the historic period can be linked to an aging population, heightened…
Prominent Drugs For Benign Prostatic hypertrophy Market Trend for 2025: Innovati …
What Are the Projected Growth and Market Size Trends for the Drugs For Benign Prostatic hypertrophy Market?
The market size for benign prostatic hypertrophy medication has seen considerable growth in recent years. It is projected to increase from $4.28 billion in 2024 to $4.58 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. The significant growth during the historic period can be linked to an aging population, heightened…
Shaping the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment M …
How Big Is the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, there has been robust growth in the market size of benign prostatic hyperplasia (BPH) treatment devices and equipment. The market, which stood at $1.29 billion in 2024, is anticipated to increase to $1.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%.…
